A phase 2, Multicenter, Open-Label Study to Assess PK/PD of SEG101 (crizanlizumab), with or without Hydroxyurea/Hydroxycarbamide, in Adult Sickle Cell Patients with Vaso-Occlusive Crisis

Type of Cancer
Hematological Malignancies

Sponsor
Novartis Pharmaceuticals

Protocol Number
CSEG101A2202

To Learn More Call
(201)-510-0950